{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Novartis India Ltd
Novartis India Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges
Novartis India Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in technical indicators despite ongoing financial challenges. The upgrade, effective from 04 Feb 2026, is driven primarily by improvements in technical trends, while valuation and financial performance remain under pressure. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change.
Novartis India Ltd Sees Technical Momentum Shift Amid Mixed Market Signals
Novartis India Ltd has experienced a notable shift in its technical momentum, moving from a bearish to a mildly bearish trend, accompanied by a 6.43% surge in its share price on 5 Feb 2026. Despite this positive price movement, key technical indicators present a complex picture, reflecting mixed signals across weekly and monthly timeframes that investors should carefully consider.
Why is Novartis India Ltd falling/rising?
On 04-Feb, Novartis India Ltd witnessed a significant price rise of 6.43%, closing at ₹827.40, reflecting a strong short-term momentum despite some underlying financial challenges and subdued long-term returns.
Novartis India Ltd is Rated Strong Sell
Novartis India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook.
Novartis India Declines 3.42%: 3 Key Factors Driving the Weekly Downturn
Novartis India Ltd’s stock declined by 3.42% over the week ending 30 January 2026, closing at Rs.759.30 compared to Rs.786.15 the previous Friday. This underperformance contrasted with the Sensex’s 1.62% gain during the same period, reflecting mounting operational challenges and bearish technical signals that weighed on investor sentiment throughout the week.
Novartis India Ltd Faces Bearish Momentum Amid Technical Indicator Shifts
Novartis India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock’s technical landscape reveals a complex interplay of bullish and bearish signals across weekly and monthly timeframes, underscoring the challenges facing investors in the Pharmaceuticals & Biotechnology sector.
Novartis India Ltd Reports Declining Quarterly Performance Amid Negative Financial Trend
Novartis India Ltd has reported a marked deterioration in its financial performance for the quarter ended December 2025, with key metrics such as net sales, profit after tax, and operating margins showing significant contraction. This downturn contrasts sharply with the company’s historical trend of stable growth, signalling challenges ahead for investors in the Pharmaceuticals & Biotechnology sector.
Are Novartis India Ltd latest results good or bad?
Novartis India Ltd's latest results are concerning, with a 36.8% decline in net profit and a 7.63% drop in revenue in Q3 FY26, indicating operational challenges and difficulties in maintaining sales momentum. The company's financial health is further strained by issues in working capital management and declining profitability.
Novartis India Q3 FY26: Profit Slumps 36.8% as Operational Challenges Mount
Novartis India Ltd., the Indian subsidiary of Swiss pharmaceutical giant Novartis AG, reported a sharp decline in profitability for Q3 FY26, with net profit tumbling 36.8% quarter-on-quarter to ₹16.09 crores from ₹24.22 crores in Q2 FY26. The disappointing results, announced in late December 2025, sent the stock into a tailspin, with shares currently trading at ₹782.95—down 28.82% from their 52-week high of ₹1,099.90. The company, which commands a market capitalisation of ₹1,933.17 crores, is grappling with margin compression and operational headwinds that have raised serious questions about its near-term trajectory.
Novartis India Ltd is Rated Sell
Novartis India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Novartis India Ltd is Rated Sell
Novartis India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Novartis India Ltd is Rated Sell
Novartis India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 December 2025, providing investors with an up-to-date view of the company's performance and outlook.
Novartis India Sees Revision in Market Evaluation Amidst Challenging Performance
Novartis India has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment comes amid subdued financial trends and a cautious market stance, highlighting the challenges faced by the small-cap pharmaceutical player in maintaining momentum within a competitive sector.
Novartis India Sees Revision in Market Evaluation Amidst Challenging Performance
Novartis India has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment. This adjustment comes amid a backdrop of subdued financial trends and technical indicators, impacting the pharmaceutical company's standing within its sector.
Why is Novartis India falling/rising?
As of 06-Nov, Novartis India Ltd's stock price is Rs 840.55, down 2.04%, and has underperformed its sector and the Sensex over the past year. The stock is in a bearish trend, trading below all major moving averages, with a year-to-date decline of 8.62%.
Is Novartis India overvalued or undervalued?
As of November 4, 2025, Novartis India is fairly valued with a PE ratio of 19.90, lower than some peers but has underperformed the Sensex with a return of -19.75% over the past year.
Is Novartis India overvalued or undervalued?
As of October 31, 2025, Novartis India is considered overvalued with a PE ratio of 20.06 and negative EV ratios, indicating weaker performance compared to peers like Sun Pharma and Cipla, and a year-to-date stock return of -5.85% versus the Sensex's 7.42%.
Is Novartis India overvalued or undervalued?
As of October 31, 2025, Novartis India is considered overvalued with a PE ratio of 20.06 and a year-to-date return of -5.85%, underperforming compared to its peers and the Sensex.
Is Novartis India overvalued or undervalued?
As of October 31, 2025, Novartis India is considered overvalued with a PE ratio of 20.06, underperforming the Sensex with a year-to-date return of -5.85%, while its peers have higher or more attractive valuations.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
